Loss of GAS5 tumour suppressor lncRNA: an independent molecular cancer biomarker for short-term relapse and progression in bladder cancer patients

BACKGROUND: Bladder cancer (BlCa) heterogeneity and the lack of personalised prognosis lead to patients’ highly variable treatment outcomes. Here, we have analysed the utility of the GAS5 tumour-suppressor lncRNA in improving BlCa prognosis. METHODS: GAS5 was quantified in a screening cohort of 176...

Descripción completa

Detalles Bibliográficos
Autores principales: Avgeris, Margaritis, Tsilimantou, Anastasia, Levis, Panagiotis K., Tokas, Theodoros, Sideris, Diamantis C., Stravodimos, Konstantinos, Ardavanis, Alexandros, Scorilas, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288135/
https://www.ncbi.nlm.nih.gov/pubmed/30374124
http://dx.doi.org/10.1038/s41416-018-0320-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288135/
https://www.ncbi.nlm.nih.gov/pubmed/30374124
http://dx.doi.org/10.1038/s41416-018-0320-6

Ejemplares similares